Lantheus Sued by Novartis Entities for Patent Infringement
By Adriano Marchese
Lantheus Holdings is being sued by Swiss multinational pharmaceutical Novartis for patent infringement on a generic drug to treat specific types of neuroendocrine tumors.
According to recent filings to the Securities and Exchange Commission, the diagnostic medical imaging agents and products company and its subsidiary, Lantheus Medical Imaging, are being sued by two Novartis entities, Advanced Accelerator Applications USA and Advanced Accelerator Applications.
The company is being taken to court for patent infringement in response to its filing of the abbreviated new drug application for Lutetium, a generic version of Lutathera, indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
January 26, 2024 08:40 ET (13:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
United States